ข่าวประชาสัมพันธ์ Press Releases ข่าวย้อนหลัง หัวข้อข่าว บลอก

วันพฤหัสบดีที่ ๓๐ มิถุนายน พ.ศ. ๒๕๕๙ ๒๒:๕๕ น.

Food and Healthcare Press Releases

Photo Release: KTC and Sirindhorn National Medical Rehabilitation Heathcare—๓๐ มิ.ย. ๕๙

Dr. Supan Sridhamma, Director General, Department of Medical Services, recentlypresided over the opening ceremony of the "Knowledge to the Elder with Modern Technology" activity at Sirindhorn National Medical Rehabilitation Centre on Tiwanon Road in

Merck Welcomes ZEISS and Hamilton Thorne as New Members of the Global Fertility Alliance Heathcare—๓๐ มิ.ย. ๕๙

DARMSTADT, Germany--30 Jun--PRNewswire/InfoQuest
Not intended for U.S. based media

Merck, a leading science and technology company, today announced together with Illumina Inc., San Diego, US, and Genea Limited, Sydney, Australia, that the Global Fertility Alliance welcomed two new members. The alliance is a collaboration to advance excellence in fertility technologies and processes within the assisted reproductive treatment (ART) laboratory. Effective immediately, ZEISS, Oberkochen, Germany, an internationally leading technology enterprise operating in the optics and optoelectronics industries, and Hamilton Thorne Ltd., Beverly, Massachusetts, US, a leading provider of precision laser devices and advanced image analysis systems for ART, regenerative medicine and developmental biology research markets, are joining the alliance and its quest to improve the consistency in ART laboratories worldwide. Following the announcement of the alliance's formation at the 2015 Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE), an update on the alliance's activities will be presented

Hetero Launches Biosimilar #Bevacizumab# for the Treatment of Metastatic Colorectal Cancer (mCRC) Heathcare—๒๘ มิ.ย. ๕๙

Hetero, one of India's leading generic pharmaceutical companies, today announces the launch of Biosimilar 'Bevacizumab' in India for the treatment of metastatic colorectal cancer (mCRC) under the brand name 'Cizumab(TM)' The product has been approved by

BiologicTx(R) Announces International Expansion Of Their Paired Donation Software BiologicTx Heathcare—๒๔ มิ.ย. ๕๙

First Successful Four-Way Kidney Exchange Completed Within Two Months Of International Implementation BiologicTx (R) today announced that their Paired Donation Software, BiologicTx MatchGrid (TM), has been implemented internationally at the King Faisal

Terumo BCT Announces a $17.4 Million Funding Contract from the Biomedical Advanced Research and Heathcare—๒๒ มิ.ย. ๕๙

Terumo BCT, a global medical device manufacturing company, is pleased to announce that it has been awarded $17.4 million in initial funding from the Biomedical Advanced Research and Development Authority (BARDA) to initiate a clinical trial using the

IOF Launches 2016 Global Awareness Campaign for World Osteoporosis Heathcare—๒๐ มิ.ย. ๕๙

The International Osteoporosis Foundation (IOF) launches a call to action for this year's World Osteoporosis Day (WOD), celebrated annually worldwide on October 20th to promote awareness of osteoporosis. Under its theme of Love Your Bones: Protect Your

FDA Approves PaxVax to Manufacture Vaxchora(TM) (Oral Cholera Vaccine) at SynCo Bio Heathcare—๒๐ มิ.ย. ๕๙

SynCo Bio Partners, a world leading GMP contract manufacturer of biopharmaceuticals, today announced that one of its customers, PaxVax, has received FDA approval for Vaxchora (TM), a single-dose oral, live attenuated cholera vaccine, indicated for use in

Babies React to Their Mother#s Voice When It Is Emitted Through the Vagina From the 16th Week Of Heathcare—๑๕ มิ.ย. ๕๙

A new audio device enables pregnant women to communicate with their babies before they are born Data presented at the 25th European Congress of Perinatal Medicine The foetus moves its mouth in an exaggerated manner when it hears a human voice. This

Genetic Weight Loss Seminars at Lifestyles Fitness Centre 26th floor, Centara Grand at Heathcare—๑๕ มิ.ย. ๕๙

Lifestyles Fitness Centre, Centara Grand at CentralWorld will hold the "Genetic Weight Loss Seminars." Hosted by Dr. Kostas l. Papadopoulos (MD, Phd in Endocrinology) – The CEO of THAI StemLife. The topic of discussion will be about how effective

ADVA launches Dengue Mission Buzz Barometer tool to boost critical dengue prevention awareness and Heathcare—๑๕ มิ.ย. ๕๙

New Dengue Mission Buzz Barometer will provide a dynamic comparison of dengue preparedness across countries in Southeast Asia In support of the 6th Association of Southeast Asian Nations (ASEAN) Dengue Day, the Asian Dengue Vaccination Advocacy (ADVA)

Victoza(R) significantly reduced the risk of major cardiovascular events and death in adults with Heathcare—๑๔ มิ.ย. ๕๙

Novo Nordisk today announced that Victoza(R) (liraglutide) significantly reduced the risk of the composite primary endpoint of cardiovascular (CV) death, non-fatal myocardial infarction (heart attack) or non-fatal stroke by 13% vs placebo (95% confidence

Faster-acting insulin aspart showed a statistically significant reduction in HbA1c in type 1 Heathcare—๑๔ มิ.ย. ๕๙

Faster-acting insulin aspart improved postprandial glucose (PPG) control in type 1 and type 2 diabetes New phase 3a findings showed that faster-acting insulin aspart demonstrated a statistically significant reduction in HbA1c in type 1 diabetes,

Tresiba(R) (insulin degludec injection U-100) demonstrated significantly lower rates of overall, Heathcare—๑๓ มิ.ย. ๕๙

New findings from the two phase 3b SWITCH trials showed that treatment with long-acting basal insulin Tresiba(R) (insulin degludec injection U-100) resulted in significantly lower rates of overall, nocturnal and severe hypoglycaemia compared with insulin

ViiV Healthcare Announces FDA Approval to Lower the Weight Limit for dolutegravir in Children and Heathcare—๑๓ มิ.ย. ๕๙

Reduction of weight limit to at least 30kg means more children and adolescents will be eligible for dolutegravir ViiV Healthcare today announced that the US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for

Semaglutide Demonstrated Superior Improvements in Glycaemic Control vs Sitagliptin (SUSTAIN 2) and Heathcare—๑๓ มิ.ย. ๕๙

Findings from two phase 3a clinical trials for semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue, were presented today at the American Diabetes Association 76th Scientific Sessions.[1],[2] In the SUSTAIN 2 trial, 0.5 mg and 1.0 mg

SIRveNIB โครงการวิจัยโรคมะเร็งตับปฐมภูมิในเอเชียแปซิฟิก เสร็จสิ้นการรับสมัครผู้ป่วยเข้าร่วมการวิจัยแ Heathcare—๑๓ มิ.ย. ๕๙

การวิจัยแบบสุ่มและมีกลุ่มควบคุมเพื่อเปรียบเทียบประสิทธิภาพระหว่าง Sorafenib กับ SIR-Spheres(R) Y-90 resin microspheres ในการรักษาโรคมะเร็งตับชนิด Hepatocellular Carcinoma แบบผ่าตัดไม่ได้ ของกลุ่ม Asia-Pacific Hepatocellular Carcinoma Trials Group (AHCC)

SIRveNIB, a Major Primary Liver Cancer Study in the Asia-Pacific Region, Completes Heathcare—๑๓ มิ.ย. ๕๙

Results of Asia-Pacific Hepatocellular Carcinoma Trials Group (AHCC) Randomised Controlled Study Comparing Sorafenib and SIR-Spheres(R) Y-90 resin microspheres in the Treatment of Unresectable Hepatocellular Carcinoma (HCC) Expected in 2017 The

Baricitinib significantly reduces joint damage progression in rheumatoid arthritis in patients who Heathcare—๙ มิ.ย. ๕๙

Patients from pivotal 24-week phase 3 trial RA-BUILD who entered long-term extension study, RA-BEYOND, demonstrate baricitinib continues to inhibit radiographic progression of structural joint damage over one year Eli Lilly and Company (NYSE: LLY) and

Patient-reported outcomes across phase 3 studies of baricitinib demonstrate statistically Heathcare—๙ มิ.ย. ๕๙

Pivotal trials show treatment with baricitinib resulted in significant improvements in pain, fatigue and ability to perform daily activities compared to methotrexate – the current standard of care – and adalimumab (Humira(R))* Eli Lilly and

Consumer Health to Play a Pivotal Role in Merck#s Africa Growth Strategy Heathcare—๙ มิ.ย. ๕๙

- Consumer Health at the forefront of Merck's plans to considerably expand on the African continent over the next five years - 2016 will be an investment year in selected African countries for Merck's Consumer Health business, with a focus on its global

Results of Clinical and Patient-Reported Outcomes Data for Baricitinib in Patients with Rheumatoid Heathcare—๘ มิ.ย. ๕๙

Eli Lilly and Company (NYSE: LLY) announced that radiographic results from a long-term extension study of baricitinib, RA-BEYOND, and patient-reported outcomes data from baricitinib's phase 3 global studies will be presented, along with other phase 2b

Novo Nordisk to Present 53 Abstracts at 76th Annual American Diabetes Association Scientific Heathcare—๗ มิ.ย. ๕๙

Novo Nordisk, a global leader in diabetes care, today announced that data from 53 abstracts including 8 oral presentations will be shared at the upcoming 76th annual Scientific Sessions of the American Diabetes Association (ADA) in New Orleans, LA, from

Merck Partners with Array BioPharma and Pierre Fabre to Initiate BRAF-mutant CRC Phase III Heathcare—๖ มิ.ย. ๕๙

- BEACON CRC trial will assess efficacy of combination regime Erbitux(R) (cetuximab), binimetinib and encorafenib in BRAF-mutant metastatic colorectal cancer (mCRC) Merck, a leading science and technology company, jointly announced with Array BioPharma

Three-year Data Show Early Response to Saxenda(R) Resulted in Improvements in Weight Loss and Heathcare—๓ มิ.ย. ๕๙

Today, data from a post hoc analysis of the three-year part of the phase 3a SCALE(TM) (Satiety and Clinical Adiposity - Liraglutide Evidence) Obesity and Prediabetes trial were presented at the first European Obesity Summit (EOS 2016). Adults with